0.960
-0.12 (-11.08%)
| Previous Close | 1.08 |
| Open | 1.11 |
| Volume | 815,091 |
| Avg. Volume (3M) | 731,626 |
| Market Cap | 53,599,772 |
| Price / Book | 7.54 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2026 |
| Diluted EPS (TTM) | -0.940 |
| Total Debt/Equity (MRQ) | 84.79% |
| Current Ratio (MRQ) | 2.33 |
| Operating Cash Flow (TTM) | -34.12 M |
| Levered Free Cash Flow (TTM) | -19.63 M |
| Return on Assets (TTM) | -38.06% |
| Return on Equity (TTM) | -119.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | PDS Biotechnology Corporation | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.38 |
|
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.09% |
| % Held by Institutions | 18.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Inspirion Wealth Advisors, Llc | 31 Mar 2026 | 181,995 |
| Iron Gate Global Advisors Llc | 31 Dec 2025 | 75,016 |
| Tempus Wealth Planning, Llc | 31 Dec 2025 | 61,800 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |